Sabine Bahn is a professor of Neurotechnology, Professor & Director of the Bahn Laboratory at The

University of Cambridge , mottoeng = Literal: From here, light and sacred draughts. Non literal: From this place, we gain enlightenment and precious knowledge. , established = , other_name = The Chancellor, Masters and Schola ...

, a Professor of Translational Neuropsychiatry at Erasmus Medical Centre Bahn's research in The Bahn laboratory at Cambridge is focused on researching the molecular basis of neuropsychiatric diseases; using molecular profiling methods to investigate abnormalities in tissues, blood and fluids; as well as developing new methods for diagnosing and treating psychiatric disorders, in particular focussing on schizophrenia and mood disorders. The Bahn laboratory is supported by laboratory facilities at the Department of Chemical Engineering and Biotechnology, Cambridge and has received funding through the Stanley Medical Research Institute (SMRI), in addition to being partnered with the Stanley Program for Epidemiology, Prevention and Treatment of Schizophrenia (SPECTS).

Work

Sabine Bahn is a practising

psychiatrist A psychiatrist is a physician who specializes in psychiatry, the branch of medicine devoted to the diagnosis, prevention, study, and treatment of mental disorders. Psychiatrists are physicians and evaluate patients to determine whether their sy ...

and honorary consultant in psychiatry at the Peterborough and Cambridge NHS trust

Psynova

Bahn founded Psynova Neureotech in 2005, which is a company specialising in the commercial applications of biomarkers for mental illnesses. In 2011, Psynova Neurotech was bought by

Myriad Genetics Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic bas ...

, a

NASDAQ The Nasdaq Stock Market () (National Association of Securities Dealers Automated Quotations Stock Market) is an American stock exchange based in New York City. It is the most active stock trading venue in the US by volume, and ranked second ...

listed diagnostics company.

Psyomics

Bahn co-founded Psyomics with Dan Cowell, who is the CEO, in March 2015. The company aims to improve the identification and diagnosis processes of mental health issues, through the use of digital tools, biological tests and scientific research. This could help the patient access and understand treatment options available. Currently, the team is working on developing tools for early detection in the workplace, as well as concentrating on diagnosing depression and bipolar disorder in a clinical context.

Achievements

Professor Bahn has published over 180 articles in well-known scientific journals and has co-founded 2 spin-out companies, (Pysnova and Psyomics). In 2015 Bahn was made a Fellow of the

Royal Society of Biology The Royal Society of Biology (RSB), previously called the Society of Biology, is a learned society and professional association in the United Kingdom created to advance the interests of biology in academia, industry, education, and research. Fo ...

. She is a fellow of Lucy Cavendish College in the

Publications

* E. Schwarz, Y. Levin, L. Wang, M. Leweke & S. Bahn - 'Peptide correlation: A means to identify high quality quantitative information in large scale proteomic studies', ''J.Sep. Sci'', August, 7;30(14): 2190-2197, (2007). * Y. Levin, E. Schwarz, L. Wang, M. Leweke & S. Bahn - 'Label free LC-MSMS quantitative proteomics for large scale biomarker discovery in complex samples', ''J.Sep. Sci'', August 2;30(14): 2198-2203, 2007). * T.J. Huang, F.M. Leweke, T.M. Tsang, D. Koethe, C.W. Gerth, B.M. Nolden, S. Gross, K. Schreiber, E. Holmes & S. Bahn - 'CSF metabolic and proteomic profiles in patients prodromal for psychosis', ''PLoS One'', August 22;2:e756, (2007). * E. Schwarz, Y. Levin, L. Wang, M. Leweke & S. Bahn - 'Peptide correlation: A means to identify high quality quantitative information in large scale proteomic studies', ''J.Sep. Sci'', August, 7;30(14):2190-2197, (2007). * S. Bahn - 'Gene expression in bipolar disorder and schizophrenia: new approaches to old problems', ''Bipolar Disord''., 4, Suppl 1:70-2, (2002).

Reviews

* K.E. Wilson, M.M. Ryan, J.E. Prime, P.D. Pashby, P.R. Orange, G. O'Beirne, J.G. Whateley, S. Bahn & C.M. Morris - 'Functional Genomics and Proteomics: Application in Neurosciences'. ''J. Neurology Neurosurg Psychiatry'', 75(4):529-538, (2004). * S. Bahn, M. Ryan, S. Augood, M. Mimac & P. Emson - 'Gene expression in the post-mortem human brain - no cause for dismay', ''J. Chem. Neuroanat''., 22, 79-94, (2001).

Books/ Book chapters

* S. Hemby & S. Bahn (editors) - ''Functional Genomics and Proteomics in the Clinical Neurosciences,'' Elsevier, (2006). * S. Bahn - 'Gene expression in psychotic disorders: dissecting the basis of complex neuropsychiatric disorders', ''Search for the Causes of Schizophrenia, Volume 5'', Gattaz & Haefner (editors), Springer, (2004). * M. Starkey, S. Bahn & H. Mahadeva - Indexing-based differential display', Analysing Gene Expression'', P. Lorkowski & P. Cullen (editors), Wiley-VCH, (2002). * S.Bahn & W. Wisden - 'A map of non-NMDA receptor subunit expression in the vertebrate brain derived from in situ hybridisation histochemistry', ''The Ionotropic Glutamate Receptors'', D.T. Monaghan & R.T. Wenthold (editors), Humana Press, (1996).

Sources

* Business Weekly Article Cambridge University spin-out aiming to improve patient outcomes in mental health arena''' * University of Cambridge Research New approach to drug discovery could lead to personalised treatment of neuropsychiatric disorders''' *Lucy Cavendish College Fellows *University of Cambridge Directory, Department of Chemical Engineering and Biotechnology *Cambridge Centre for Neuropsychiatric Research {{DEFAULTSORT:Bahn, Sabine Year of birth missing (living people) Living people Academics of the University of Cambridge Neuropsychologists